G1 Therapeutics Kicks off Phase 2 Study Related to Treatment of NonSmall Cell Lung Cancer
07:39 AM EDT, 05/10/2021 (MT Newswires) -- G1 Therapeutics (GTHX) has initiated a phase 2 study of cosela in patients with metastatic nonsmall cell lung cancer, or NSCLC.
The medication is administered prior to docetaxel in patients with NSCLC in the 2nd and 3rd line setting, the company said in a statement Monday. These patients have previously been treated with a checkpoint inhibitor and chemotherapy.
The placebo-controlled trial will enroll about 146 patients, who will be randomly assigned to receive cosela or placebo prior to docetaxel on day 1 of each 21-day cycle.
The primary endpoint is to evaluate the anti-tumor effect of cosela on overall survival. Secondary endpoints include the effect of the medication on other anti-tumor endpoints.
Results of the study are expected in H1 2023.
Price: 20.85, Change: +0.25, Percent Change: +1.21